Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B7KM
|
|||
| Drug Name |
Quinoline derivative 13
|
|||
| Synonyms |
PMID27724045-Compound-8
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H30ClN3O3
|
|||
| Canonical SMILES |
CC1CCCC(C1)(CNC(=O)C2=C(C=CC3=C2C=CC(=N3)N4CCC(CC4)O)Cl)O
|
|||
| InChI |
1S/C23H30ClN3O3/c1-15-3-2-10-23(30,13-15)14-25-22(29)21-17-4-7-20(26-19(17)6-5-18(21)24)27-11-8-16(28)9-12-27/h4-7,15-16,28,30H,2-3,8-14H2,1H3,(H,25,29)/t15-,23-/m0/s1
|
|||
| InChIKey |
BAHOQKHEWZJWME-WNSKOXEYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2X purinoceptor 7 (P2RX7) | Target Info | Antagonist | [1] |
| Voltage-gated potassium channel Kv11.1 (KCNH2) | Target Info | Antagonist | [1] | |
| Target's Patent Info | P2X purinoceptor 7 (P2RX7) | Target's Patent Info | [1] | |
| Voltage-gated potassium channel Kv11.1 (KCNH2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | The NLRP3 inflammasome | |||
| Voltage gated Potassium channels | ||||
| WikiPathways | Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | |||
| SIDS Susceptibility Pathways | ||||
| Hematopoietic Stem Cell Differentiation | ||||
| Potassium Channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.